• Mar. Lug 15th, 2025

adverse event

  • Home
  • Improved survival with combination of Lurbinectedin and Atezolizumab for extensive-stage small cell lung cancer #ASCO25

Improved survival with combination of Lurbinectedin and Atezolizumab for extensive-stage small cell lung cancer #ASCO25

Results from a global phase 3 clinical trial found that maintenance therapy with a combination of lurbinectedin and atezolizumab helped some patients with extensive-stage small cell lung cancer (ES-SCLC) live…